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Immunoglobulin G (IgG) monoclonal antibodies (mAbs) are 
a major class of medicines, with high specificity and affinity 
towards targets spanning many disease areas. The antibody Fc 
(fragment crystallisable) region is a vital component of existing 
antibody therapeutics as well as many next generation biologic 
medicines. The size and complexity of these molecules make 
them difficult to characterise using conventional methods. 
Thermodynamic stability is a critical property for the 
development of stable and effective therapeutic proteins. Here, 
for the first time, a combination of ion-mobility mass 
spectrometry (IM-MS) and hydrogen/deuterium exchange mass 
spectrometry (HDX-MS) approaches have been used to inform 
on the global and local conformation and dynamics of 
engineered IgG Fc variants with reduced thermodynamic 
stability. The changes in conformation and dynamics have been 
correlated with their thermodynamic stability to better 
understand the destabilising effect of functional IgG Fc 
mutations and to inform engineering of future therapeutic 
proteins. 
In 2013, seven of the top ten selling drugs were 
therapeutic proteins, each grossing more than $5.5 billion 
annually.[1] Five of these medicines were monoclonal antibodies 
and another a fusion of an antibody Fc region to the ligand 
binding portion of human tumour necrosis factor (TNF) receptor. 
These drugs have been used to treat a number of different 
conditions including autoimmune disorders (Adalimumab, 
Etanercept and Infliximab) and cancers (Trastuzumab and 
Bevacizumab). There has been much recent interest in the 
treatment of cancer using novel antibody-based approaches, 
such as effector-enhanced, polyspecific and toxin-carrying 
antibodies. Molecular engineering efforts to modulate antibody 
properties, such as immune system recruitment, serum half-life 
extension and cytotoxic payload attachment are typically 
focused in the Fc region of IgG antibodies. This versatility 
demonstrates why the Fc region is a vital component of many 
protein drug molecules in clinical development. 
In contrast to small-molecule drugs, protein therapeutics 
are much larger and consequently have significantly more 
dynamic freedom.[2] Only a subset of these conformations will 
possess the desired activities (e.g. target binding) and some will 
be unstable.[3] These conformational dynamics are intrinsically 
related to thermodynamic stability and are implicated in the 
colloidal stability of the protein: for instance, structures may be 
populated that expose aggregation-prone motifs.[4] These 
fluctuations may not be appreciably reversible, and can lead to a 
degradation of the protein drug. 
Central to the drive to better understand the relationship 
between molecular structure, dynamics and stability is the 
development of analytical techniques that are spatially and 
conformationally resolved. Large and flexible molecules, such as 
monoclonal antibodies, are often difficult to study using high-
resolution techniques, such as X-ray crystallography[5] and 
NMR.[6] Mass spectrometry (MS) is a core technology in the 
study of protein therapeutics due to its high selectivity, specificity 
and sensitivity.[7] Higher order structural information can be 
obtained by utilising emerging structural mass spectrometry 
techniques, including ion mobility and hydrogen/deuterium-
exchange coupled to mass spectrometry (IM-MS and HDX-MS, 
respectively). 
IM-MS is a gas phase electrophoretic technique that 
informs shape-defining parameters of the molecule, previously 
applied to the study of IgGs.[7e,8] HDX-MS reveals structure and 
dynamics of the protein’s local environment, by monitoring labile 
hydrogen atoms in a polypeptide as they exchange with those in 
solvent.[9,10] 
In this study, IM-MS and HDX-MS approaches have been 
utilised that, in combination, yield information on the global and 
local conformational dynamics of the antibody Fc region. 
Functional IgG1 mutants which have been engineered for 
reduced immune system recruitment and increased serum half-
life have been studied here for the first time and the 
thermodynamic destabilisation exhibited when the mutations are 
combined has been examined. 
We compared the molecular (global) and sub-molecular (local) 
conformational dynamics of four human IgG1 Fc variants: a 
variant containing a triple mutation (TM) in the CH2 domain 
(L234F/L235E/P331S) that results in a decrease in affinity for Fc 
γ-receptor type IIIA (FcγRIIIA) and abrogates antibody 
dependent cellular cytotoxicity (ADCC)[11]; a YTE variant, 
containing a triple mutation in the CH2 domain 
(M252Y/S254T/T256E) that results in an increase in neonatal Fc 
receptor (FcRn) affinity at endosomal pH (~6.6) leading to a 4-
fold increase in serum half-life in humans[12]; a TM/YTE variant, 
which contains both TM and YTE mutations; and a wild type 
(WT) IgG1 antibody, which contains neither TM or YTE 
mutations. 
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We investigated the possibility that the introduction of 
these mutations could lead to a loss of thermodynamic stability. 
The thermal unfolding transitions for the CH2 domain from 44 
IgG1 antibodies were obtained using differential scanning 
calorimetry (DSC). The midpoint of the first unfolding transition 
(Tm1) was taken as a measure of the equilibrium 
thermodynamic stability of the CH2 domain
 (Figure 1).[13] 
 
. 
Figure 1. Thermal stability by DSC for WT, TM, YTE and TM/YTE IgG1 
antibodies. Midpoints of the first unfolding transition, assigned to the CH2 
domain, are shown. Bars denote mean ±1 S.D. 
Wild type human CH2 domains were found to be more 
stable (mean Tm1 70.1±0.7 ˚C). Thermal stability was found to 
be reduced in both TM (mean Tm1 64.1±0.4 ˚C) and YTE (mean 
Tm1 62.2±1.2 ˚C) variants. The inclusion of all six mutations led 
to a further decrease in the observed thermal stability of the CH2 
domain (mean Tm1 58.1±1.4 ˚C). This combined effect may 
indicate negative co-operativity, although a purely additive effect 
is within error (Figure S1 in Supporting Information). If there is 
thermodynamic cooperativity between the two sets of mutations, 
then it is possible that a common site or sites within the protein 
may be responsible for translating the mutations into a 
difference in stability (ΔΔGD-N). This hypothesis formed the basis 
of the subsequent structural dynamics studies. 
The global conformational dynamics of the IgG1 variant Fc 
regions were studied: shape and dynamics of the Fc region 
provide information on whether the mutations impact global 
stability via gross changes in structure and/or conformational 
dynamics. X-ray crystal models for the Fc region of the WT [14], 
TM [11a] and YTE [12a] variants reveal that the WT and YTE are 
highly similar, but that there are large CH2 domain translation 
and rotation differences in the TM structure (Figure S3). 
The Fc variants exhibit a similar charge state distribution 
when analysed bv native-MS; in all cases the 11+ - 14+ are 
present (Figure S4), consistent with previous studies on IgG1 Fc. 
[7e] The distribution of these charge states changes, between 
mutants. The WT-Fc has the narrowest distribution, centred on 
the 12+ and 13+ ions. The TM, YTE and TM-YTE mutants exhibit 
an increasingly broader charge state distribution, with higher 
relative intensities of the 11+ and 14+ charge states. Proteins 
with intrinsic disorder are known to exhibit wider charge state 
distributions than highly structured proteins.[15] The observed 
widening of the charge state distribution suggests the mutations 
may act to destabilise the structure of the Fc domain.  
 
 
Figure 2. Global conformational ensembles for the Fc regions (54.7 kDa) of 
four engineered IgG1 variants. Collision cross section (CCS) variation with 
increasing molecular charge (11+:14+) were calculated from IM-MS drift time 
chromatograms under identical source and travelling wave conditions (see 
Supporting Information for experimental detail). 
IM-MS has been used to inform on the conformation 
adopted by each charge state (Fig. 2). The 11+ and 12+ charges 
overlay, suggesting the ions have a similar molecular size at 
these charge states. Increasing the charge on a protein adds a 
gas-phase unfolding force, observed in the four Fc variants. 
Each Fc follows a common unfolding transition, with similar CCS 
values estimated for each structure (Table S5). The 13+ and 14+ 
charge states show significant difference in the arrival time 
distributions between mutants. For the 13+ charge the TM and 
YTE variants show an increase in the intensity of the extended 
populations when compared to the wild type, whilst for the 14+ 
charge state the WT retains a higher intensity of compact 
conformation relative to the TM and YTE variants. The data 
suggests that the introduction of the mutations may serve to 
destabilise the protein, lowering the energy barrier required to 
induce gas-phase unfolding relative to the wild type. The 
differences observed in the TM and YTE variants become more 
pronounced in the TM/YTE variant; consistent with the DSC data 
the TM and YTE mutations in tandem appear to have a 
cooperative effect on reducing the energy required to induce Fc 
unfolding.
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Figure 3. HDX of the IgG1 CH2 domain interior surface. (a) Four overlapping peptides span the region of largest magnitude change in HDX between WT and 
TM/YTE (orange). (b) X-ray crystal structure of wild type Fc (3AVE) predicts that four of the amide nitrogen atoms (blue spheres) are involved in stable hydrogen 
bonds (sticks: acceptor amino acids), which would confer significant protection to HDX. Green: YTE mutations. (c) D-label exchanged over time for the 
overlapping peptides for the four variants (black squares: WT; red triangles: TM; blue circles: YTE; purple triangles: TM/YTE). Unobservable amino acids (prolines 
and N-termini) in grey. X denotes Met in WT and TM and Tyr in YTE and TM/YTE. 
To investigate whether the thermodynamic differences 
were related to local conformational dynamics for these 
engineered IgG variants, HDX-MS experiments were carried out 
on isolated Fc regions. Sub-molecular localisation was provided 
by analysis of individual peptides that result from proteolytic 
digestion of the intact protein after deuterium labelling. The 
coverage and redundancy of the peptide map defines the 
detection and resolution at which structure and conformational 
dynamics may be observed. The peptide maps for all four Fc 
variants resulted in a sequence coverage of 93.8% and a 
redundancy of 5.4 (Figure S5). Each peptide in the map was 
monitored for deuterium incorporation following dilution into 95% 
D2O. 
Three mutations in the antibody sequence in either the 
upper or lower CH2 domain (TM and YTE variants, respectively) 
have an impact on structure and/or conformational dynamics 
throughout the entire Fc region (Figure S6). These effects are 
both local to the site of mutation and also long ranging, reaching 
the posterior surface of the CH3 domain – a distance of 65 Å 
from the first TM mutation. The mutations predominantly induce 
deprotection to HDX, which results from increased exposure to 
solvent (as in a less compact conformational ensemble) and/or a 
reduction in intramolecular hydrogen-bonding. This is consistent 
with the trend observed in the DSC experiments; suggesting that 
the lower thermodynamic stability has a significant component 
derived from the protein (as opposed to solvent) enthalpy and 
entropy. 
HDX-MS permits spatial resolution of the sites within the Fc that 
contribute to this effect. The experiments reveal that the interior 
CH2 surface has the largest net change in deuterium 
incorporation between the wild type and the TM/YTE variant. 
Four degenerate peptides were identified that span β1-α1 of the 
CH2 domain (Figure 3). Each show that TM and YTE mutations 
increased rates of deuterium incorporation relative to wild type. 
This observation is increased when the mutations are present 
together (Tables S1-4). An F-test analysis indicated that, for the 
TM/YTE variant, a two-state model did not adequately fit the 
hydrogen-exchange observed in this region (P < 0.0002 for all 
peptides). Using a three-state model, backbone amide groups 
exchanging for deuterium at an intermediate rate were observed, 
with a concomitant decrease in the number of amides 
undergoing exchange at the slow rate i.e. Aslow ≈ 
TM/YTEAslow + 
TM/YTEAinter. In the wild type and with TM or YTE mutations alone 
a two-state model was adequate to describe the hydrogen-
exchange data (P ≥ 0.93). This small change is seen for multiple 
ions in all four overlapping peptides, significantly outside error. 
This suggests that, cooperatively, the TM/YTE mutations may 
increase the rate or extent of conformational dynamics in this 
region of the protein (Figure 3). 
 In this study we have applied a combination of emerging 
structural mass spectrometry techniques to investigate global 
(native IM-MS) and local (HDX-MS) conformational dynamics in 
a major class of medicine: therapeutic monoclonal antibodies. 
For the first time, these techniques have been used together to 
rationalise destabilising effect of mutations in the IgG1 Fc region 
that serve to abrogate recruitment of natural killer cells (TM) or 
to enhance in vivo serum half-life (YTE). Native MS analysis 
suggested minor conformational changes upon mutation, 
evidenced by changes in charge state distribution. IM-MS 
suggests that the gas phase energy barrier to unfolding may 
have been reduced in the dual TM/YTE mutant. HDX-MS 
experiments reveal a number of long range disruptions to protein 
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conformation. The largest changes in conformational dynamics 
were at the interior face of the CH2 domain (β1-α1). Further 
statistical analysis suggests that there is a cooperative effect on 
the local structure and dynamics at this location, brought about 
by combining structurally distant TM and YTE mutations. In 
combination, the biophysical tools have been able to show that 
the mutations locally destabilise the CH2 interior surface, without 
significantly disturbing the global conformation of the Fc region. 
Taken together, these findings may explain the clear 
thermodynamic trend among a large number of antibodies 
tested and highlight a focused region of the molecule for future 
stability engineering work. The data presented here illustrate the 
power of MS-based technologies for the study of molecular 
structure and dynamics, notably in the field of therapeutic protein 
engineering and development where other, more established, 
structural techniques have proven to be relatively intractable. 
We anticipate that these techniques will be used to focus 
mutagenesis campaigns in efforts to increase thermodynamic 
stability in next generation antibody and Fc-fusion protein 
therapeutics. 
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